Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

188P - Efficacy of SARS-CoV-2 based mRNA vaccines for patients with thoracic malignancies with 6 months follow up: A prospective observational study

Date

03 Apr 2022

Session

Poster Display session

Topics

COVID-19 and Cancer

Tumour Site

Thoracic Malignancies

Presenters

Urska Janzic

Citation

Annals of Oncology (2022) 33 (suppl_2): S117-S121. 10.1016/annonc/annonc858

Authors

U. Janzic1, K. Mohorcic1, L. Mrak1, M. Ivanovic2, U. Bidovec Stojkovic1, J. Debeljak1, P. Korosec1, M. Rijavec1

Author affiliations

  • 1 University Clinic of Respiratory and Allergic Diseases Golnik, Golnik/SI
  • 2 University Clinical centre Maribor, Maribor/SI
More

Abstract 188P

Background

Vaccination against SARS-CoV-2 in patients (pts) with thoracic malignancies is crucial since they are at high risk of having severe COVID-19 disease course. Still, data on efficacy of vaccination in this pt population are scarce.

Methods

Prospective observational study of pts with solid cancers on active anticancer treatment (chemotherapy, immunotherapy with immune checkpoint inhibitors (ICI) or targeted therapy (TT)) that received mRNA-based SARS-CoV-2 vaccination was performed. Pts were sampled before, 2-3 weeks after the first, 2-3 weeks after the second dose, 3 and 6 months after the complete primary course of vaccination. Detection of anti-SARS-CoV-2 S1 IgG antibodies in serum was determined with commercial ELISA assay IDK®. Samples with ≥ 175 ng/ml were considered positive. Here we present data on pts with thoracic malignancies.

Results

Ninety-two pts were included in the analysis. Median age at diagnosis was 63 years, 49% were female and 93% were currently receiving anticancer therapy. Pts were treated for NSCLC, SCLC and malignant pleural mesothelioma in 90%, 5% and 5%, respectively. Eighteen pts had previous exposure to COVID-19. Out of 74 COVID-19 naïve pts, seroconversion after 1st vaccination was 61%, after 2nd 96%, and seropositivity 3 and 6 months after 2nd vaccination 94% and 95%, respectively. According to treatment type, pts treated with chemotherapy, chemo + ICI, ICI alone or TT achieved seroconversion after 2nd vaccination in 100%, 83%, 96% and 100%, and mostly maintained positive levels of anti-SARS-CoV-2 S1 IgG antibodies 6 months after 2nd vaccination with 100%, 100%, 89% and 95%, respectively. However, there was a marked decrease in anti-SARS-CoV-2 S1 IgG antibody level of 69% in average 3 months after and 80% in average 6 months after the 2nd vaccination in pts with thoracic malignancies (both P < 0.001).

Conclusions

Pts with thoracic malignancies achieve high proportion of seroconversion after two doses of mRNA-based vaccines, yet, anti-SARS-CoV-2 S1 IgG antibody levels decline substantially 3 and 6 months after the 2nd vaccination, thus the 3rd dose of vaccine is reasonable to provide adequate protection against severe COVID-19 disease course.

Legal entity responsible for the study

The authors.

Funding

Slovenian Research Agency (Grant no. P3-0360).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.